Sanofi Net Invested Capital vs Capital Stock Analysis
SNY Stock | USD 49.13 0.23 0.47% |
Sanofi ADR financial indicator trend analysis is much more than just breaking down Sanofi ADR prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sanofi ADR is a good investment. Please check the relationship between Sanofi ADR Net Invested Capital and its Capital Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.
Net Invested Capital vs Capital Stock
Net Invested Capital vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sanofi ADR Net Invested Capital account and Capital Stock. At this time, the significance of the direction appears to have strong relationship.
The correlation between Sanofi ADR's Net Invested Capital and Capital Stock is 0.61. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Sanofi ADR, assuming nothing else is changed. The correlation between historical values of Sanofi ADR's Net Invested Capital and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Sanofi ADR are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Net Invested Capital i.e., Sanofi ADR's Net Invested Capital and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.61 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from Sanofi ADR's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sanofi ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.At this time, Sanofi ADR's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 203.7 M in 2024, despite the fact that Discontinued Operations is likely to grow to (110.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 26.9B | 31.7B | 26.5B | 21.8B | Total Revenue | 39.2B | 45.4B | 43.1B | 31.0B |
Sanofi ADR fundamental ratios Correlations
Click cells to compare fundamentals
Sanofi ADR Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sanofi ADR fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 112.7B | 114.5B | 120.2B | 124.6B | 126.5B | 88.2B | |
Short Long Term Debt Total | 25.9B | 23.7B | 22.4B | 21.2B | 18.4B | 13.7B | |
Other Current Liab | 298M | 32M | 127M | 425M | 13.9B | 14.6B | |
Total Current Liabilities | 20.4B | 19.3B | 21.3B | 24.0B | 24.2B | 14.3B | |
Total Stockholder Equity | 58.9B | 63.0B | 68.7B | 73.1B | 74.0B | 50.2B | |
Property Plant And Equipment Net | 11.0B | 10.6B | 12.0B | 11.7B | 11.8B | 8.5B | |
Net Debt | 16.5B | 9.8B | 12.3B | 8.5B | 9.7B | 7.6B | |
Accounts Payable | 15.3B | 15.4B | 17.4B | 18.8B | 7.3B | 9.1B | |
Cash | 9.4B | 13.9B | 10.1B | 12.7B | 8.7B | 6.1B | |
Non Current Assets Total | 83.8B | 80.7B | 89.6B | 90.5B | 95.8B | 66.2B | |
Non Currrent Assets Other | (5.4B) | (4.0B) | (4.4B) | (5.1B) | 738M | 774.9M | |
Cash And Short Term Investments | 9.4B | 13.9B | 10.1B | 12.7B | 8.7B | 6.9B | |
Net Receivables | 10.1B | 1.2B | 612M | 374M | 11.0B | 6.4B | |
Good Will | 44.5B | 44.4B | 48.1B | 49.9B | 49.4B | 33.9B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Short Term Investments | 426M | 900M | 1.1B | 664M | 270M | 256.5M | |
Liabilities And Stockholders Equity | 112.7B | 114.5B | 120.2B | 124.6B | 126.5B | 88.2B | |
Non Current Liabilities Total | 33.2B | 32.1B | 29.9B | 27.1B | 27.9B | 23.5B | |
Inventory | 19.2B | 18.6B | 19.9B | 20.9B | 9.7B | 11.4B | |
Other Current Assets | (9.8B) | 83M | 89M | 85M | 1.2B | 1.0B | |
Other Stockholder Equity | (47.9B) | (56.4B) | (59.0B) | (64.3B) | (871M) | (827.5M) | |
Total Liab | 53.4B | 51.2B | 51.2B | 51.6B | 52.1B | 37.8B | |
Property Plant And Equipment Gross | 11.0B | 10.6B | 12.0B | 11.7B | 27.4B | 28.8B | |
Total Current Assets | 28.9B | 33.8B | 30.7B | 34.1B | 30.7B | 22.0B | |
Accumulated Other Comprehensive Income | 52.6B | 56.7B | 62.2B | 68.2B | 4.9B | 4.6B | |
Short Term Debt | 4.8B | 3.0B | 3.5B | 4.5B | 2.3B | 2.9B | |
Intangible Assets | 16.6B | 18.4B | 21.4B | 21.6B | 73.6B | 77.3B | |
Other Liab | 12.1B | 11.4B | 11.0B | 10.8B | 12.5B | 11.9B | |
Current Deferred Revenue | 3.8B | 822M | 319M | 264M | 597M | 567.2M | |
Retained Earnings | 51.8B | 60.1B | 63.0B | 66.7B | 67.5B | 64.1B | |
Other Assets | 8.8B | 11.4B | 13.5B | 12.9B | 14.8B | 9.8B | |
Long Term Debt | 20.1B | 19.7B | 17.1B | 14.9B | 14.3B | 12.7B | |
Property Plant Equipment | 11.0B | 10.6B | 12.0B | 11.7B | 13.4B | 10.5B | |
Deferred Long Term Liab | 2.3B | 6.1B | 7.7B | 6.2B | 7.2B | 4.0B | |
Long Term Investments | 5.3B | 7.1B | 8.0B | 9.2B | 2.7B | 2.5B | |
Short Long Term Debt | 4.6B | 2.8B | 3.2B | 4.2B | 2.0B | 3.2B | |
Net Tangible Assets | 177M | 6.3B | 6.9B | 9.5B | 8.5B | 4.6B |
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Transaction History View history of all your transactions and understand their impact on performance | |
Stocks Directory Find actively traded stocks across global markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 2.3 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.